|

Zimberelimab Clinical Trials

13 actively recruiting trials across 9 locations

Also known as: AB122, GLS-010, GS-0122, anti-PD-1 monoclonal antibody AB122

Other4 trials

A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer
Phase 2
PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer
Phase 2
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
Phase 3
Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC
Phase 2

Birmingham, Alabama1 trial

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

University of Alabama at Birmingham

Phase 1

Tucson, Arizona1 trial

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

The University of Arizona Cancer Center-North Campus

Phase 2

La Jolla, California1 trial

Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

University of California San Diego

Phase 1

Palo Alto, California1 trial

Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors

Stanford Cancer Center

Phase 1

New Haven, Connecticut1 trial

A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies

Yale- New Haven Hospital- Yale Cancer Center

Phase 1

Tampa, Florida1 trial

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

Moffitt Cancer Center

Phase 1/2

Indianapolis, Indiana1 trial

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Phase 2

New York, New York1 trial

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

Columbia University Irving Medical Center / NewYork-Presbyterian Hospital

Phase 2

Pittsburgh, Pennsylvania1 trial

Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma

UPMC Hillman Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.